トバルディ・セラピューティクス
Tvardi Therapeutics, Inc.
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.73 | $0 | — |
| 2025 Q4 | -0.78 | $0 | -$6M |
| 2025 Q3 | -0.59 | $0 | -$4M |
| 2025 Q2 | 0.51 | $0 | -$9M |
| 2025 Q1 | -0.52 | $3M | -$5M |
| 2024 Q4 | -5.04 | $0 | -$4M |
| 2024 Q3 |
| -8.19 |
| $0 |
| -$14M |
| 2024 Q2 | -13.17 | $0 | -$13M |